

Form PTO-1595
1-31-92

DOCUMENT ID NO.: 10231162

U.S. Department of
Patent and Trademark

RECORDATION FORM COVER SHEET

PATENTS ONLY

Our Ref.: 620-161

Commissioner of Patents and Trademarks
Box Assignment, Washington, D.C. 20231

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Cancer Research Ventures Limited
5 Alfred Place
London, United Kingdom WC1E 7EBAdditional name/s of conveying party/ies attached? ☐

3. Nature of conveyance:

- ☐ Assignment ☐ Merger
☐ Security Assignment ☐ Change of Name
☒ Other Deed of Assignment

Execution Date: October 31, 2002

2. Name and address of receiving party(ies):

Cancer Research Technology Limited

Name: ~~Cancer Research Campaign Technology Limited~~

Internal Address: _____

Street Address: 61 Lincoln's Inn FieldsCity: LondonState/Country: United KingdomZip: WC2A 3PXAdditional name/s & address/es attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No(s).

- (1) 09/922.652
 (2) 09/898.461
 (3)

B. Patent No(s).

- (1) 6,303,323
 (2)
 (3)

Additional numbers attached ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: B. J. Sadoff

Internal Address: _____

Street Address: Nixon & Vanderhye P.C.1100 North Glebe Road8th FloorCity: Arlington State: VA Zip: 222016. Total number of applications & patents involved: 3

7. Total fee (37 CFR 3.41)

\$ 120.00☐ Enclosed☒ Authorized to be charged to deposit account #14-1140
Previously paid December 4, 2002 - post
card receipt attached.8. The Commissioner is hereby authorized to charge any
deficiency in the fee(s) filed, or asserted to be filed, or which
should have been filed herewith (or with any paper thereafter
filed in this application by this firm) to our Account No.
14-1140.

DO NOT USE THIS SPACE

9. Statements and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy
of the original document.B. J. Sadoff

Name of Person Signing

Reg. No. 36,663



Signature

May 5, 2003

Date

Total number of pages including original cover sheet, attachments, and document: [19]

CH \$120.00 141140 09922662

700039223

PATENT
REEL: 013852 FRAME: 029484

THIS DEED OF ASSIGNMENT is made the 31st day of OCTOBER 2002

BETWEEN:

- (1) **CANCER RESEARCH VENTURES LIMITED** a company registered in England (registered number 3521378) whose registered office is situated at 5 Alfred Place, London WC1E 7EB (the "Assignor"); and
- (2) **CANCER RESEARCH TECHNOLOGY LIMITED** (formerly known as **CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED**) a company registered in England (registered number 1626049) whose registered office is situated at 61 Lincoln's Inn Fields, London WC2A 3PX (the "Assignee")

WHEREAS:

In accordance with an agreement 30 September 2002 made between the Assignor and the Assignee, it was agreed that all of the Assignor's right, title and interest in and to the Assignor Intellectual Property (as defined below) shall be assigned to Assignee, subject to and with the benefit of any encumbrances (including any licence or other agreements) relating to such Assignor Intellectual Property, on the following terms and conditions.

NOW THIS DEED WITNESSES as follows:

1. DEFINITIONS AND INTERPRETATION

- 1.1 In this Assignment and in the Schedule to this Agreement the following words and phrases shall have the following meanings unless the context requires otherwise:

"Assignment" means this deed of assignment and any and all schedules, appendices and other addenda to it as may be varied from time to time in accordance with the provisions of this assignment.

"Assignor Intellectual Property" means the Assignor Patent Rights, but excluding any right that is by way of or in the nature of a licence.

"Assignor Patent Rights" means the patents and patent application particulars of which are set out in Schedule 1 together with any Patent Rights which claim priority or are derived therefrom or which claim the same subject matter as such patents and patent applications.

"Parties" means the Assignors and Assignee and "Party" shall be construed accordingly.

"Patent Rights" means any patent applications, patents, author certificates, inventor certificates, utility certificates and all foreign counterparts of them and includes all divisions, renewals, continuations, continuations-in-

- 2 -

part, extensions, reissues, substitutions, confirmations, registrations, revalidations and additions of or to them, as well as any SPC, or like form of protection.

"SPC"

means a right based on a patent pursuant to which the holder of the right is entitled to exclude third parties from using, making, having made, selling or otherwise disposing or offering to dispose of, importing or keeping the product to which the right relates, such as Supplementary Protection Certificates in Europe, and any similar right anywhere in the world.

- 1.2 The headings used in this Assignment shall not affect its interpretation except in the Schedule.

2. ASSIGNMENT

- 2.1 The Assignor HEREBY ASSIGNS to the Assignee absolutely, subject to and with the benefit of any and all encumbrances (including without limitation any licence or other agreements), all of its right, title and interest throughout the world in and to:

2.1.1 the Assignor Intellectual Property (including all right, title and interest in Canada and the United States of America and all other countries of the world);

2.1.2 all rights and powers arising or accrued from the Assignor Intellectual Property including the right to recover and take all such proceedings as may be necessary for the recovery of damages and/or other remedies in respect of all infringements whether committed before or after the date of this Assignment and to have the benefit of any remedy obtained on any infringement or alleged infringement before the date of this Assignment; and

2.1.3 the right to apply for, prosecute and to obtain Patent Rights in any part of the world (including but not limited to Canada and the United States) in respect of the Assignor Patent Rights and to claim priority from the date of any application embodied in the Assignor Patent Rights, with the intent that the grant of any patents or similar protection shall be in the name of and vest in Assignee.

- 2.2 The Assignor hereby requests the relevant authorities in all countries of the world to issue any patents granted for the invention described in the Assignor Patent Rights in the name of Assignee or its successors or assigns in accordance with this Assignment.

3. FURTHER ASSURANCE

- 3.1 At the request and cost of the Assignee and without unreasonable delay, the Assignor shall sign, execute, make and do all such further deeds, documents, acts and things as Assignee may reasonably require to give effect to this Assignment and to allow Assignee to enjoy the full benefit of the rights hereby assigned.

- 3 -

4. GENERAL

- 4.1 Failure by any of the parties to enforce at any time or for any period any one or more of the terms or conditions of this Assignment shall not be a waiver of them or the rights at any time subsequently to enforce all terms and conditions of this Assignment.
- 4.2 This Assignment shall be binding upon the Assignors' successors and shall enure to the benefit of any successors and/or assigns of Assignee and references to a Party shall include reference to its successors and/or assigns.

5. GOVERNING LAW AND JURISDICTION

- 5.1 All matters relating to this Assignment shall be governed by English law and the Parties submit to the exclusive jurisdiction of the courts of England and Wales.

SCHEDULE I

Assignor Patent Rights

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Regent 4	Improvements Relating to Cancer Therapy	016/0005 - Mewburn Ellis	US	09/898461 (Publication no.: US 2002 - 0090709-A1)	5/7/01	Priority Application
Regent 5	Improved Antibodies	016/0007 - JA Kemp & Co US	US	60/392,354	1/7/02	Priority Priority
Bermonds 1	Expression System	037/0018 - Kilburn & Strude	UK UK US US	0130955.8 0218556.9 60/377482 TBC	24/12/01 9/8/02 2/5/02 9/8/02	Priority Application Application Application
Blow 1	Assay Methods	051/0005 - Mewburn Ellis	UK	0209508.1	2/4/02	Priority Priority
Cauper 2	HIB01	008/0038 - Mewburn Ellis	UK	0127344.0	14/11/01	Priority Priority

CDDGP0035 / 0012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
DarlIng 2	Materials & methods relating to Increasing Retroviral Titre	060/0006 - Mewburn Ellis	UK	009619.8	18/4/00	Nationals
			UK	013731.6	14/2/01	Priority
			PCT	PCT/GB01/01261	22/3/01	Priority
			AU	TBC	18/11/02	PCT
			CA	TBC	18/10/02	Application
			CN	TBC	18/10/02	Application
			EP	TBC	18/11/02	Application
			HK	TBC	"	Application
			INDIA	TBC	18/11/02	Application
			JP	TBC	18/10/02	Application
			KR	TBC	18/11/02	Application
			NZ	TBC	18/11/02	Application
			SG	TBC	18/10/02	Application
			US	TBC	18/10/02	Application
						Nationals
DAIXAA 1	Compounds having anti- tumor & antibacterial properties	019/0003 - D Young & Co.	AT	EP0278176	22/12/87	Granted
			BE	EP0278176	22/12/87	Granted
			CH	EP0278176	22/12/87	Granted
			DE	P3789299.1	22/12/87	Granted
			ES	EP0278176	22/12/87	Granted
			FR	EP0278176	22/12/87	Granted
			GR	3012092	22/12/87	Granted
			HK	1080801	10/12/97	Granted
			IT	EP0278176	22/12/87	Granted
			JP	325109/87	22/12/87	Granted
			LU	EP0278176	22/12/87	Granted
			NL	EP0278176	22/12/87	Granted
			SE	EP0278176	22/12/87	Granted
			UK	EP0278176	22/12/87	Granted
			US	07/912,466 (US5281620)	13/7/92	Granted

CDGP/005 / 0012 A

- 6 -

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
DMXAA 2	Cancer Therapy	019/0003 - D Young & Co.	NZ PCT	336259 PCT/NZ00/00098 (WO00/76597)	14/6/99 14/6/00	Nationals Priority PCT
			EP	942571.1	8/1/02	Application
			JP	01-502830	14/12/01	Application
			NZ	516564	11/1/02	Application
			US	10/014887	11/12/01	Application
DMXAA 3	Combination therapy for cancer	019/0003 - D Young & Co.	NZ JP US EP	NZ503199 232871/00 09/774,002 01307370.5	3/3/00 1/8/00 31/1/01 30/8/01	Nationals Priority Application Application Application
DMXAA 4	Cancer Therapy by combination therapy	019/0003 - D Young & Co.	NZ PCT	NZ 506060 PCT/NZ01/00154 (WO02/09700)	28/7/00 22/7/01	PCT Priority PCT
DMXAA 5	Anticancer compounds	019/0003 - D Young & Co.	UK PCT	01212851.1 PCT/GB02/004025	3/9/01 3/9/02	PCT Priority PCT
DMXAA 6	Combination with NSAIDs	019/0003 - D Young & Co.	UK	0206839.3	22/3/02	Priority Priority

CDGP/005 / 0012 A

-7-

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Gaken I	Materials & Methods relating to the expression of genes - Fusngine	060/0005 - Newburn Ellis	UK	9810999.4	21/5/98	Priority
			PCT	PCT/GB99/01609	21/5/99	Application
			AU	40508/00	21/5/99	Application
			CA	2333144	27/12/00	Application
			CN	99808292.9	5/1/01	Application
			EP	99923745.6	31/5/99	Application
			HK	01103431.0	17/5/01	Application
			INDIA	IN/PCT/2000/00627	12/12/00	Application
			INDONESIA	W-20002666	20/12/00	Application
			JP	2000-549741	21/1/00	Application
			KR	TBC	21/1/00	Application
			NZ	508863	14/12/00	Application
			SG	200006708-2	21/1/00	Application
			US	09/700731	20/1/00	Application
						Nationals
Glover I	Inhibiting Gene Expression (RNAi)	047/0005 - Kilburn & Strode	UK	GB 9923444.1	19/1/99	Priority
			PCT	PCT/GB00/04404	17/1/00	Application
				(WG01/36646)		
			AU	14063/01	23/5/02	Application
			CA	TBC	TBC	Application
			EP	00976188.3	17/1/00	Application
			IL	149666	14/5/02	Application
			JP	2001-538524	20/5/02	Application
			MX	PA/a/2002/005013	17/5/02	Application
			NO	2002 2359	TBC	Application
			NZ	519325	31/5/02	Application
			PL	TBC	17/5/02	Application
			SG	200203380-1	12/6/02	Application
			US	10/150426	17/5/02	Application
			ZA	2002/3816	14/5/02	Application

CDGP/005/0012 A

-8-

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Graham 6	Chemokine and uses thereof	009/0008 - Mewburn Ellis	UK	0207624.8	02/04/02	Priority Priority PCT
Gutberg 1	Materials and methods relating to nucleic acid amplification and profiling	023/0004 - Mewburn Ellis	UK UK PCT	0025913.5 0107547.2 PCT/GB01/04707 (WO02/34942)	23/10/00 26/3/01 23/10/01	Priority Priority Application PCT
Hadfield 1	Materials & methods for synthesising stilbenes	010/0022 - Mewburn Ellis	UK PCT	0031263.7 PCT/GB01/05534	21/12/00 14/12/01	Priority Application PCT
Hadfield 2	Substituted Stilbenes & their reactions	010/0023 - Mewburn Ellis	UK UK PCT	0031262.9 0100295.5 PCT/GB01/05702	21/12/00 5/3/01 20/12/01	Priority Priority Application PCT
Jackman 2	Anti-Cancer Compounds CH300919 Series of Compounds	008/0022 - JA Kemp & Co	UK PCT AU CA EP JP US	GB 9904275.6 PCT/GB00/00655 (WO00/50417) 26838/00 2364708 00905212.7 2000-60098 09/914,010	24/2/99 24/2/00 31/8/01 21/8/01 16/8/01 24/8/01 19/10/01	Priority Application Application Application Application Application Application

CIDGP/005/0012.A

- 9 -

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Luskey 3	Determination of Cellular Growth Abnormality	047/0007 - Newburn Ellis	UK	9722217.8	21/10/97	Nationals
			UK	9724134.3	14/11/97	Priority
			UK	9804156.9	26/2/98	Priority
			UK	9810360.4	15/5/98	Priority
			UK	9817075.6	5/8/98	Priority
			PCT	PCT/GB98/03153 (WO99/21014)	21/10/98	Published 29/4/99
			AU	9895502	21/10/98	Application
			CA	2305872	21/10/98	Application
			EP	98949123.8	21/10/98	Application
			JP	11-523482	21/10/98	Granted
			NZ	508996	21/10/98	Granted
			UK	2332515B	22/12/97	Provisional
			US	60/071245	27/5/98	Provisional
			US	60/086885	16/10/01	Provisional
			US	60/095966	21/10/98	Granted
			US	09/175947 (6303323B1)	8/7/01	Divisional
			US	09/922652		PCT
Marshall 2	MARK	008/0025 - Newburn Ellis	UK	0106641.4	16/3/01	Priority
			PCT	PCT/GB02/01282	18/3/02	PCT

C:\DGP\005\0012.A

- 10 -

PROJECT	PATENT TITLE	CHV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Minneci I	Materials and methods relating to the treatment of leukaemias	027/0007 - Mewburn Ellis	UK PCT	0007217.3 PCT/GB01/01274	24/3/00 22/3/01	PCT Priority PCT PCT
Neldle 6	Therapeutic Acridone and Acridine Compounds	008/0029 - Mewburn Ellis	US PCT	US 60/216624 PCT/GB01/03046 (WO02/08193)	7/7/00 6/7/01	Priority Application Priority
Neldle 7	Therapeutic Acridone and Acridine Compounds	009/0039 - Mewburn Ellis	US	60/347899	5/1/02	Priority Priority
Neldle 8	Crystal Structure of G-Quadruplex	008/0042 - Mewburn Ellis	UK	0207623.0		Priority Nationals
Pelleci I	Materials and methods relating to the effects of P66 expression	027/0006 - Mewburn Ellis	UK PCT AU CA EP JP US	9906515.3 PCT/GB00/01079 (WO00/56866) 0033124 2367464 00911131.1 2000-606745 09/937182	22/3/99 22/3/00 22/3/00	Priority PCT Application Application Application Application Application

CDGP/005 / 0012 A

PROJECT	PATENT TITLE	CRY FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Plasterk 1	Vectors and Methods for Providing Cells with Additional Nucleic Acid Material Integrated in the Genome of Solid Cells	0370010 - Verelinge	EP	EP96200298.6	9/2/96	Priority
			PCT	PCT/NL97/00040 (WO97/29202)	7/2/97	Application
			EP	97902729.9	9/2/98	Application
			AU	16746/97	23/7/98	Application
			CA	2244812	31/7/98	Application
			JP	9-528410	7/8/98	Application
			US	08/909786	12/8/97	Withdrawn
			US(CIP)	09/317062 - 6,051,430	12/8/97	Granted
			US	09/117985	7/8/98	Withdrawn
			US (CIP)	09/731289	6/12/00	Application
Plasterk 2	Vectors and Methods for Providing Cells with Additional Nucleic Acid Material Integrated in the Genome of Solid Cells	0370010 - Verelinge	Nationals			Nationals
			PCT	PCT/NL98/00456 (WO99/07871)	11/8/98	
			AU	87528/98	17/5/99 & 30/6/99	
			CA	2301198	17/5/99	
			EP	98939015.8	30/6/99	
			IP	TBC	TBC	
			MX	1495	11/2/00	
			NZ	502894	16/2/00	
			US	09/502624	11/2/00	
			US			

CDGP/005 / 0012 A

- 12 -

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Schellens 1	BCRP	037/0016 - Nederlandsch Octrooibureau	NL	1012066	17/5/99	Nationals
			NL	1012481	30/6/99	Priority
			PCT	PCT/NL00/00331	17/5/00	Application
			EP	009317207	TBC	Application
			US	09/988285	TBC	Application
Shamkhani 1	Material and methods relating to the increase of protein activity	078/0003 - Newburn Ellis	UK	0015426.0	24/6/00	PCT
			PCT	PCT/GB01/02810	25/6/01	Priority
Shamkhani 3	Multimeric Proteins	078/0008 - JA Kenp & Co	UK	0125093.5	18/10/01	Priority
Splis 1	Stat 5 materials and methods relating to the production and maintenance of cell lines	037/0017 - Newburn Ellis	UK	0130223.1	18/12/01	Priority
			UK	0206085.1	14/3/02	Priority
			UK	0206086.1	14/3/02	Priority

CDGP0035/0012 A

- 13 -

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Stevens I	Benzothiazole Compounds for Use in Therapy 2-aryl benzothiazole compounds CJMI26	071/0004 - Wilson Gunn Sterrett	UK	GB 9317949.7	28/8/93	Nationals
			PCT	PCT/GB94/01883 (WO95/06469)	30/8/94	Priority Application
			AT	182077	30/8/94	Granted
			BE	0721336	30/8/94	Granted
			CJL	0721336	30/8/94	Granted
			DE	69419517	30/8/94	Granted
			DK	0721336	30/8/94	Granted
			ES	ES213357173	30/8/94	Granted
			FR	0721336	30/8/94	Granted
			GR	0721336	30/8/94	Granted
			IE	0721336	30/8/94	Granted
			IT	0721336	30/8/94	Granted
			LU	0721336	30/8/94	Granted
			MC	0721336	30/8/94	Granted
			NL	0721336	30/8/94	Granted
			PORTUGAL	0721336	30/8/94	Granted
			SE	0721336	30/8/94	Granted
			UK	0721336	30/8/94	Granted
			AU	690577	30/8/94	Granted
			CA	2170508	30/8/94	Application
JP	508001/1995	30/8/94	Application			
US	5874431	28/2/96	Granted			

CDG/P085 / 0012 A

- 14 -

PROJECT	PATENT TITLE	GRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Stevens 2	Benzazole Compounds 2- Arylbenzazole Compounds	071/0005 - Wilson Gunn Skerrett	UK PCT EP AU CA JP US	GB 9503946.7 PCT/GB96/00440 96004181.3 711052 2213737 526096/1996 6034246	28/2/95 28/2/96 28/2/96 28/2/96 28/2/96 28/2/96 28/2/97	Nationals
						Priority
						Application
						Application
						Granted
						Application
Stevens 4	2 Arylbenzazole Compounds	071/0007 - Wilson Gunn Skerrett	UK PCT	GB 9919673.5 PCT/GB00/03210 (WQ01/14354)	20/8/99 21/8/00	Nationals
						Priority
						Application
						Application
						Application
						Application
Stevens 5	Therapeutic Polycyclic Compounds	071/0008 - Mewburn Ellis	AU CA EP JP US	67085/00 2382406 00954726.6 51844/2001 10/069018	21/8/00 21/8/00 21/8/00 19/2/02 20/2/02	PCT
						Priority
						Application
						Application
						Application
						Application
Stevens 6	Therapeutic Compounds	071/0009 - Mewburn Ellis	US PCT	US 60239267 PCT/GB01/04557	12/10/00 12/10/01	PCT
						Priority
						Application
						Application
						Application
						Application

CDGP/005 / 0012 A

PROJECT	PATENT TITLE	CRV FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Stevenson 1	Improvements in or relating to immune response modification	078/0005 - Mewburn Ellis	UK	9220808.1	2/10/92	Nationals
			PCT	PCT/GB93/02054 (WO94/08008)	4/10/93	Priority Application
			AU	48324/93 - 685399	4/10/93	Granted
			CA	2,145,064	4/9/93	Application
			EP	93921048.0	4/10/93	Application
Stevenson 2	Materials and methods relating to immune Responses	078/0006 - Mewburn Ellis	JP	508859/1994	4/10/93	Application
			US (CIP)	08/896,535	18/7/97	Application
			UK	0009470.6	17/4/00	Nationals
			PCT	PCT/GB01/01719 (WO01/79510)	17/4/01	Priority Application
			EP	TBC	16/10/02	Application
Stevenson 3	Materials and methods relating to fusion of proteins for inducing an Immune Response	078/0009 - Mewburn Ellis	JP	TBC	16/10/02	Application
			US	TBC	16/10/02	Application
			UK	0028319.2	20/11/00	PCT
			PCT	PCT/GB01/05142 (WO02/40513)	20/11/01	Priority Application
			UK	0205395.7	7/3/02	Priority
Stevenson 4	Materials and methods relating to the treatment of lymphoma	078/0009 - Mewburn Ellis	UK			Priority

CDG/005 / 0012 A

- 16 -

PROJECT	PATENT TITLE	CRY FILE REF. & AGENT	COUNTRY	APPLICATION/PATENT NO.	FILING DATE	STATUS
Valant 1	Materials and methods for modulating T-cell activity	037/0011 - Newburn Ellis	UK	0127602.1	16/11/01	Priority
Workman 1	Indole-3 Acetic Acid Derivatives	011/0002 - Newburn Ellis	UK	0016162.0 PCT/GB01/02872 (WO02/02110)	30/6/00 30/6/01	Priority Application
Workman 2	Therapeutic compounds and their uses in therapy (HSP90)	008/0034 - Newburn Ellis	UK	0130733.9	21/12/01	Priority
Workman 3	Assay, Methods and Means	008/0034 - Newburn Ellis	UK	0202871.0	12/7/02	Priority

CDGIP/005/0012 A


- 17 -

IN WITNESS WHEREOF this Assignment has been executed as a deed by the parties' duly authorised representatives and delivered on the day and year first before written

EXECUTED as a DEED by
CANCER RESEARCH
TECHNOLOGY LIMITED acting by:

KANPALES. KANAN
Director

CLIVE STANWAT
Director/Secretary



Clive Stanway

EXECUTED as a DEED by
CANCER RESEARCH VENTURES
LIMITED acting by:

KEITH BLUNDY
Director

GEORGE PICKERING
Director/Secretary



C.D.G. Pickering



UNITED STATES
PATENT AND
TRADEMARK OFFICE

B35
620-761
Assign Ave
5/11/03

APRIL 11, 2003

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

NIXON & VANDERHYE P.C.
B.J. SADOFF
1100 NORTH GLEBE ROAD
8TH FLOOR
ARLINGTON, VA 22201



102311602A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF NON-RECORDATION OF DOCUMENT

DOCUMENT ID NO.: 102311602

THE ENCLOSED DOCUMENT HAS BEEN EXAMINED AND FOUND NON-RECORDABLE BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. THE REASON(S) FOR NON-RECORDATION ARE STATED BELOW. DOCUMENTS BEING RESUBMITTED FOR RECORDATION MUST BE ACCOMPANIED BY A NEW COVER SHEET REFLECTING THE CORRECT INFORMATION TO BE RECORDED AND THE DOCUMENT ID NUMBER REFERENCED ABOVE.

THE ORIGINAL DATE OF FILING OF THIS ASSIGNMENT DOCUMENT WILL BE MAINTAINED IF RESUBMITTED WITH THE APPROPRIATE CORRECTION(S) WITHIN 30 DAYS FROM THE DATE OF THIS NOTICE AS OUTLINED UNDER 37 CFR 3.51. THE RESUBMITTED DOCUMENT MUST INCLUDE A STAMP WITH THE OFFICIAL DATE OF RECEIPT UNDER 37 CFR 3. APPLICANTS MAY USE THE CERTIFIED PROCEDURES UNDER 37 CFR 1.8 OR 1.10 FOR RESUBMISSION OF THE RETURNED PAPERS, IF THEY DESIRE TO HAVE THE BENEFIT OF THE DATE OF DEPOSIT IN THE UNITED STATES POSTAL SERVICE.

SEND DOCUMENTS TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231. IF YOU HAVE ANY QUESTIONS REGARDING THIS NOTICE, YOU MAY CONTACT THE INDIVIDUAL WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723.

1. THE COVER SHEET SUBMITTED FOR RECORDING IS NOT ACCEPTABLE. TO RECORD A DOCUMENT IN THE ASSIGNMENT DIVISION, A DOCUMENT MUST ACCOMPANY THE COVER SHEET.

SHARON BROOKS, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

COPY

**COVERSHEET SUBMITTED
WITHOUT SUPPORTING
DOCUMENTS.**

**EXAMINER, PLEASE DEEM
NON-RECORDABLE**

Nixon & Vanderhye P.C.

ATTORNEYS AT LAW

8TH FLOOR
1100 NORTH GLEBE ROAD
ARLINGTON, VIRGINIA 22201-4714

August 6, 2003

TELEPHONE: (703) 816-4000
FACSIMILE: (703) 816-4100
WRITER'S DIRECT DIAL NUMBER:
(703) 816-4091
E-MAIL: BJS@nixonvan.com

VIA FACSIMILE - 703-306-5995

U.S. Patent and Trademark Office
Assignment Division,
Box Assignments, CG-4
1213 Jefferson Davis Hwy, Suite 320
Washington, D.C. 20231

Subject: DOCUMENT ID NO.: 102311602 - U.S. Patent No. 6,303,323 and
Applications Ser. Nos. 09/922,652 and 09/898,461

Dear Sir:

On May 5, 2003, we responded to the Notice of Non-Recordation of Document ID No. 102311602 dated April 11, 2003. In submitting the response to Non-Recordation a new Assignment cover sheet was filed which incorrectly identified the receiving party as Cancer Research *Campaign* Technology Limited--it should have read **Cancer Research Technology Limited**. As of this date Notice of Recordation of this resubmission of Assignment has not been received in our office.

In a telephone conversation today between the undersigned's assistant, Peggy Coester, and Ms. Sharon Brooks of the Assignment Division it was determined that the filing of the marked up cover sheet and the following attached items faxed to the above facsimile number would resolve this problem.

The following are attached for your convenience.

Marked-up cover sheet of May 5, 2003 (according to Ms. Brooks instructions);
Copy of May 5, 2003 cover letter;
Post Card Receipt (date stamped by PTO on December 4, 2002);
Copy Original Cover Sheet dated May 5, 2003;
Copy of Assignment as filed on December 4, 2002 (executed October 31, 2002);
Copy of Document No.: 102311602 (Notice of Non-Recordation of Document);
and
Copy of December 4, 2002 Recordation Cover Sheet with Cash Register Receipt.

Correction of this submission is hereby respectfully requested.

Please contact the undersigned if further clarification or documentation is necessary.

Form PTO-1595
1-31-92

DOCUMENT ID NO.: 10231162

U.S. Department of Commerce
Patent and Trademark Office

RECORDATION FORM COVER SHEET

PATENTS ONLY

Our Ref.: 620-161

Commissioner of Patents and Trademarks
Box Assignment, Washington, D.C. 20231

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Cancer Research Ventures Limited 5 Alfred Place London, United Kingdom WC1E 7EB Additional name/s of conveying party/ies attached? ☐ 3. Nature of conveyance: ☐ Assignment ☐ Merger ☐ Security Assignment ☐ Change of Name ☒ Other <u>Deed of Assignment</u> Execution Date: <u>October 31, 2002</u>	2. Name and address of receiving party(ies): Name: <u>Cancer Research Campaign Technology Limited</u> Internal Address: _____ Street Address: <u>61 Lincoln's Inn Fields</u> _____ _____ City: <u>London</u> State/Country: <u>United Kingdom</u> Zip: <u>WC2A 3PX</u> Additional name/s & address/es attached? ☐ Yes ☒ No
--	---

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No(s).

(1) 09/922,652
(2) 09/898,461
(3)

B. Patent No(s).


(1) 6,303,323
(2)
(3)Additional numbers attached ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>B. J. Sadoff</u> Internal Address: _____ Street Address: <u>Nixon & Vanderhye P.C.</u> <u>1100 North Glebe Road</u> <u>8th Floor</u> City: <u>Arlington</u> State: <u>VA</u> Zip: <u>22201</u>	6. Total number of applications & patents involved: <u>3</u> 7. Total fee (37 CFR 3.41) \$ <u>120.00</u> ☐ Enclosed ☒ Authorized to be charged to deposit account #14-1140 Previously paid December 4, 2002 - post card receipt attached. 8. The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper thereafter filed in this application by this firm) to our Account No. 14-1140.
---	---

DO NOT USE THIS SPACE

9. Statements and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

B. J. SadoffName of Person Signing
Reg. No. 36,663

Signature

May 5, 2003

Date

Total number of pages including original cover sheet, attachments, and document:

[19]

COPY

PATENT
REEL: 043852 FRAME: 02764

DATED 31 OCTOBER 2002

CANCER RESEARCH VENTURES LIMITED

- and -

CANCER RESEARCH TECHNOLOGY LIMITED

INTELLECTUAL PROPERTY ASSIGNMENT

I certify that this is a true copy of the original document.

C.D.G. Pickering
C.D.G. Pickering
Solicitor of the Supreme Court of England and Wales
(Roll number 199245)

COPY